As the CEO and co-founder of AcuraStem, Mr. Samuel V. Alworth stands at the forefront of a revolution in neuroscience, spearheading the development of effective treatments for central nervous system disorders. Under Alworth's leadership, AcuraStem is pioneering patient-based therapeutics in the field of neurodegeneration, with a primary focus on advancing new treatments for ALS and FTD.

With an impressive track record spanning over 20 years in the life sciences, Mr. Alworth brings a wealth of experience encompassing research, drug development, and business development. His technical expertise extends to the application of artificial intelligence and machine learning technologies in life science assay platforms. Since 2010, Mr. Alworth has been instrumental in advancing the fields of spinal muscular atrophy, ALS, and FTD disease modeling through the establishment of significant translational collaborations. These collaborations include influential partnerships with Takeda, the Alzheimer Drug Discovery Foundation, the Harrington Discovery Institute, Harvard University, Nikon Corporation, and with AcuraStem co-founder Dr. Justin Ichida at the University of Southern California.

Mr. Alworth's career highlights include leading the development of an AI-enabled drug discovery software, SVCell (later acquired by Leica), showcasing his commitment to pushing the boundaries of innovation. His contributions are underscored by numerous issued and pending patents, as well as scientific journal publications.